French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and weight control drug semaglutide to just once a month, according to new research to be presented at this year’s annual meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).
Centessa’s public offering; Vivoryon ends Ph2 Alzheimer’s trial
Plus, news about EXO Biologics: Centessa prices public offering: The startup aims to raise $93.5 million, or up to $107.6 million if all options are